SCHEMBL5546764

SCHEMBL5546764

COC(=O)CCN1CCc2ccccc2C1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.68
HDAC1 Q13547 2/20 0.68
HDAC8 Q9BY41 2/20 0.68
NCOR2 Q9Y618 2/20 0.68
KDM4E B2RXH2 1/20 0.63
ALOX15 P16050 1/20 0.63
PRMT5 O14744 7/20 0.62
WDR77 Q9BQA1 7/20 0.62
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
USP2 O75604 1/20 0.60
TAAR1 Q96RJ0 1/20 0.60
HTR1A P08908 2/20 0.58
DRD2 P14416 2/20 0.58
HTR2A P28223 2/20 0.58
SLC6A4 P31645 2/20 0.58
HTR7 P34969 2/20 0.58
HRH1 P35367 2/20 0.58
DRD3 P35462 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7276869 0.86 HDAC3 (0.60) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL5862011 0.85 KMT2A (0.61) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL3477555 0.81 HDAC3 (0.70) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL3891857 0.80 HDAC3 (0.68) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL30945664 0.80 POLB (0.65) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL10244533 0.80 POLB (0.65) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL30945656 0.80 POLB (0.65) HDAC3HDAC1HDAC8NCOR2KDM4E
Hydrochloric Acid SCHEMBL4251907 0.79 HDAC3 (0.67) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL10514635 0.78 HDAC3 (0.54) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL31093171 0.78 HTR1A (0.84) HDAC3HDAC1HDAC8NCOR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-03-03 US claimed
EP-1303311-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF Neurochem, Inc. (CA) 2003-04-23 EP claimed
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (GI) 2002-08-22 US claimed
WO-2002007781-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF NEUROCHEM INC. (CA) 2002-01-31 WO claimed
US-7311893-B2 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-12-25 US disclosed
US-7311893-B2 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-12-25 US disclosed
US-7183367-B2 Vinyl sulphone modified polymer N.V. ORGANON (NL) 2007-02-27 US disclosed
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-03-03 US disclosed
EP-1303311-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF Neurochem, Inc. (CA) 2003-04-23 EP disclosed
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (GI) 2002-08-22 US disclosed
WO-2002007781-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF NEUROCHEM INC. (CA) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof APP, APBA1, BACE1 HDAC3 4632/4885HDAC1 4744/4885HDAC8 4629/4885
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof APP, APBA1, BACE1 HDAC3 4632/4885HDAC1 4744/4885HDAC8 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.